Treatment of obesity: comparison of physician and nonphysician therapists using placebo and anorectic drugs in a double-blind trial. 1977

R L Atkinson, and F L Greenway, and G A Bray, and W T Dahms, and M E Molitch, and K Hamilton, and J Rodin

In a randomized double-blind trial, 60 obese patients were assigned in groups of 12 to five therapists. The patients for each therapist were then randomly assigned in groups of four to placebo or one of two preparations of mazindol. Ninety-three percent of the patients completed the nine weeks of treatment. Weight loss averaged 1.1 lb per week and there was no advantage to pharmacological agents over placebo. However, there were significant differences between therapists. Weight loss by the patients assigned to physicians was no better than for those assigned to nonphysician personnel, but there were significant differences between individual nonphysician personnel. These findings support the concept that nonphysician personnel may be effective in treating many obese patients. In addition, we could not find a significant effect of either form of mazindol when compared to placebo.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008454 Mazindol Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter. AN-448,Diestet,Mazanor,Mazindole,Sanjorex,Sanorex,Solucaps,Teronac,Teronak,AN448
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D010820 Physicians Individuals licensed to practice medicine. Physician
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002140 California State bounded on the east by Nevada and Arizona, on the south by Mexico and the Pacific Ocean on the south and west, and on the north by Oregon.
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic

Related Publications

R L Atkinson, and F L Greenway, and G A Bray, and W T Dahms, and M E Molitch, and K Hamilton, and J Rodin
August 1974, The New Zealand medical journal,
R L Atkinson, and F L Greenway, and G A Bray, and W T Dahms, and M E Molitch, and K Hamilton, and J Rodin
April 1969, The Medical journal of Australia,
R L Atkinson, and F L Greenway, and G A Bray, and W T Dahms, and M E Molitch, and K Hamilton, and J Rodin
February 1969, The Medical journal of Australia,
R L Atkinson, and F L Greenway, and G A Bray, and W T Dahms, and M E Molitch, and K Hamilton, and J Rodin
March 1969, The Medical journal of Australia,
R L Atkinson, and F L Greenway, and G A Bray, and W T Dahms, and M E Molitch, and K Hamilton, and J Rodin
April 1990, Journal of ethnopharmacology,
R L Atkinson, and F L Greenway, and G A Bray, and W T Dahms, and M E Molitch, and K Hamilton, and J Rodin
January 1982, Acta psychiatrica Scandinavica,
R L Atkinson, and F L Greenway, and G A Bray, and W T Dahms, and M E Molitch, and K Hamilton, and J Rodin
January 1985, Nutrition and health,
R L Atkinson, and F L Greenway, and G A Bray, and W T Dahms, and M E Molitch, and K Hamilton, and J Rodin
June 1966, Archives of disease in childhood,
R L Atkinson, and F L Greenway, and G A Bray, and W T Dahms, and M E Molitch, and K Hamilton, and J Rodin
July 2012, Journal of hypertension,
R L Atkinson, and F L Greenway, and G A Bray, and W T Dahms, and M E Molitch, and K Hamilton, and J Rodin
June 2003, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!